CD274 and neoplasm: The results of this meta-analysis confirm previous observations that the Ventana PD-L1 (SP142) assay’s analytical sensitivity is significantly lower than that of the three other Food and Drug Administration-approved PD-L1 assays and that the diagnostic sensitivity of Ventana PD-L1 (SP142) against PD-L1 IHC 22C3 pharmDx, PD-L1 IHC 28-8 pharmDx, and Ventana PD-L1 (SP263) assays is prohibitively low for both the 1% and the 50% tumor proportion score in non-small cell lung cancer and other tumor models.